What it is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not a peptide. It is studied for supporting fat metabolism and boosting cellular NAD+, a molecule involved in cellular energy metabolism.
In the PeptidesAI encyclopedia, 5-Amino-1MQ is categorized under weight management. The research described on this page is preclinical, meaning it comes from cell and animal studies rather than from trials in people.
How it's thought to work
5-Amino-1MQ is studied as an inhibitor of NNMT, an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor. In obese and diabetic mice, NNMT expression is increased in white adipose (fat) tissue and liver. Inhibiting NNMT increases cellular NAD+ and SAM, and in adipocytes (fat cells) it increases oxygen consumption and suppresses lipogenesis (fat production).
What the research says
Studies in cells and in diet-induced obese mice found that a potent NNMT inhibitor reduced body weight and white fat mass, decreased fat cell size and lowered plasma total cholesterol. Knocking down NNMT in white fat and liver also protected mice against diet-induced obesity.
No human clinical trials were found for this page, and the evidence for NNMT inhibition as an approach to obesity is still early-stage.
Reported side effects
No published human safety data was found for 5-Amino-1MQ. In the mouse study, NNMT inhibitors did not change total food intake and no observable adverse effects were reported. Long-term human safety is unknown.
Form
5-Amino-1MQ is sold as oral capsules, so it is not reconstituted.
Important notes
5-Amino-1MQ is not FDA-approved and is not a peptide; it is an oral NNMT inhibitor sold as a research chemical. The evidence is early-stage, and because the product is not regulated, its quality and purity are not independently verified.
Sources
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.. Neelakantan H et al. Biochemical Pharmacology, 2018. Preclinical
- Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.. Kraus D et al. Nature, 2014. Preclinical
Frequently asked questions
These questions cover the same ground as the sections above, in a shorter format.
What is 5-Amino-1MQ?
An oral small-molecule NNMT inhibitor (not a peptide) studied in animal and cell models for effects on fat metabolism and NAD+. It is not FDA-approved.
How is 5-Amino-1MQ thought to work?
It is studied as an inhibitor of the enzyme NNMT; inhibition raises cellular NAD+ and SAM and increases oxygen consumption in fat cells in laboratory studies.
What does the research on 5-Amino-1MQ say?
Preclinical studies show NNMT inhibition reducing body weight and fat mass in diet-induced obese mice; no human clinical trials were found.
What are the reported side effects of 5-Amino-1MQ?
No published human safety data was found. Mouse studies reported no observable adverse effects, and long-term human safety is unknown.
The full entry, plus the calculator
The PeptidesAI app has the complete encyclopedia entry for 5-Amino-1MQ — one of 70 compounds covered — plus the reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store